Cargando…

Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Xinyu, Na, Yue, Yin, Shun, Yan, Chang, Gu, Jinlian, Zhang, Ning, Geng, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005336/
https://www.ncbi.nlm.nih.gov/pubmed/36903581
http://dx.doi.org/10.3390/molecules28052336
_version_ 1784905054930599936
author Zhong, Xinyu
Na, Yue
Yin, Shun
Yan, Chang
Gu, Jinlian
Zhang, Ning
Geng, Fang
author_facet Zhong, Xinyu
Na, Yue
Yin, Shun
Yan, Chang
Gu, Jinlian
Zhang, Ning
Geng, Fang
author_sort Zhong, Xinyu
collection PubMed
description Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimetic nanoparticles (NPs) to solve this situation. Among them, NPs can extend the half-life of drugs in the body as the “core” of the wrapped drug, and the cell membrane acts as the “shell” of the wrapped NPs to functionalize the NPs, which can further improve the delivery efficiency of nano-drug delivery systems. Researchers are learning that cell membrane biomimetic NPs can circumvent the BBB’s restriction, prevent harm to the body’s immune system, extend the period that NPs spend in circulation, and have good biocompatibility and cytotoxicity, which increases efficacy of drug release. This review summarized the detailed production process and features of core NPs and further introduced the extraction methods of cell membrane and fusion methods of cell membrane biomimetic NPs. In addition, the targeting peptides for modifying biomimetic NPs to target the BBB to demonstrate the broad prospects of cell membrane biomimetic NPs drug delivery systems were summarized.
format Online
Article
Text
id pubmed-10005336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100053362023-03-11 Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease Zhong, Xinyu Na, Yue Yin, Shun Yan, Chang Gu, Jinlian Zhang, Ning Geng, Fang Molecules Review Alzheimer’s disease (AD) is to blame for about 60% of dementia cases worldwide. The blood–brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimetic nanoparticles (NPs) to solve this situation. Among them, NPs can extend the half-life of drugs in the body as the “core” of the wrapped drug, and the cell membrane acts as the “shell” of the wrapped NPs to functionalize the NPs, which can further improve the delivery efficiency of nano-drug delivery systems. Researchers are learning that cell membrane biomimetic NPs can circumvent the BBB’s restriction, prevent harm to the body’s immune system, extend the period that NPs spend in circulation, and have good biocompatibility and cytotoxicity, which increases efficacy of drug release. This review summarized the detailed production process and features of core NPs and further introduced the extraction methods of cell membrane and fusion methods of cell membrane biomimetic NPs. In addition, the targeting peptides for modifying biomimetic NPs to target the BBB to demonstrate the broad prospects of cell membrane biomimetic NPs drug delivery systems were summarized. MDPI 2023-03-03 /pmc/articles/PMC10005336/ /pubmed/36903581 http://dx.doi.org/10.3390/molecules28052336 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhong, Xinyu
Na, Yue
Yin, Shun
Yan, Chang
Gu, Jinlian
Zhang, Ning
Geng, Fang
Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title_full Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title_fullStr Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title_full_unstemmed Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title_short Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer’s Disease
title_sort cell membrane biomimetic nanoparticles with potential in treatment of alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005336/
https://www.ncbi.nlm.nih.gov/pubmed/36903581
http://dx.doi.org/10.3390/molecules28052336
work_keys_str_mv AT zhongxinyu cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT nayue cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT yinshun cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT yanchang cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT gujinlian cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT zhangning cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease
AT gengfang cellmembranebiomimeticnanoparticleswithpotentialintreatmentofalzheimersdisease